Puma Biotechnology Soars on Breast Cancer Drug Results

July 22, 2014 9:56 PM

6 0

Puma Biotechnology Inc. (PBYI:US) almost tripled in extended trading after the company said a clinical trial of its experimental drug blocked the return of breast cancer in women with a type of early-stage disease.

The drug, neratinib, improved disease-free survival by 33 percent compared with a placebo in a trial of 2,821 women with early-stage HER2-positive breast cancer, Los Angeles-based Puma said today in a statement. Disease-free survival refers to the interval a patient remains alive and free of signs o...

Read more

To category page